Given that the EGFR receptor pathway possibly plays an important role in the acquisition of tumor cell resistance to both anti-EGFR antibodies and irinotecan, the use of both drugs together might have a reciprocal effect on the accumulation of resistance. Here, EGFR is linked to neoplasm.